Login to Your Account

DUBLIN – Johnson & Johnson is beefing up its immunology pipeline – and its capabilities in developing bispecific antibodies – by acquiring Covagen AG. Financial terms were not disclosed, but, given Covagen's recent success at attracting finance, the up-front value of the deal should be comfortably north of CHF200 million (US$218 million).
SHANGHAI – China Biologic Inc., of Beijing, has topped up its controlling equity interest by 20 percent in Guizhou Taibang Biological Products Co. Ltd., in a deal valued at $87.1 million.

Huya Bioscience International, of San Diego, signed a strategic partnership with the Changzhou Center for Biotech Development (CZCBD) for the advancement of innovative drug and biomarker candidates. 

More DEALS AND M&A Headlines

Cast Your Vote

Has biotech’s bubble burst?: